Literature DB >> 2990034

Malignant transformation of erythroid cells in vivo by introduction of a nonreplicating retrovirus vector.

L Wolff, S Ruscetti.   

Abstract

DNA from a replication-defective spleen focus-forming virus (SFFV) was reconstructed and transfected into psi-2 cells containing a packaging-defective mutant of Moloney murine leukemia virus. Replication-incompetent retrovirus particles (helper virus-free containing genomes that express the transforming envelope gene of SFFV (gp52) transformed bone marrow cells in vitro and, after direct intravenous introduction of the vector, induced malignant erythroid disease in vivo. Disease induction was dependent on prior treatment of mice with phenylhydrazine, which probably increased the availability of erythroid target cells. Since there was no evidence of virus particle expression in mice with malignant disease, this study demonstrates the acute oncogenic potential of a limited number of erythroid cells expressing SFFV gp52. Direct inoculation of animals with nonreplicating retroviral vectors containing transforming genes may be useful in study the oncogenic effects of such genes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990034     DOI: 10.1126/science.2990034

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  45 in total

1.  Role of phosphatidylinositol 3-kinase in friend spleen focus-forming virus-induced erythroid disease.

Authors:  Daigo Umehara; Shinya Watanabe; Haruyo Ochi; Yukari Anai; Nursarat Ahmed; Mari Kannagi; Charlotte Hanson; Sandra Ruscetti; Kazuo Nishigaki
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  Intracellular transport and leukemogenicity of spleen focus-forming virus envelope glycoproteins with altered transmembrane domains.

Authors:  R V Srinivas; D R Kilpatrick; R W Compans
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

3.  Loss of pathogenicity of spleen focus-forming virus after pseudotyping with Akv.

Authors:  K S Jones; S Ruscetti; F Lilly
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

4.  Friend virus utilizes the BMP4-dependent stress erythropoiesis pathway to induce erythroleukemia.

Authors:  Aparna Subramanian; Shailaja Hegde; Prashanth Porayette; Michele Yon; Pamela Hankey; Robert F Paulson
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

5.  The hydrophobic membrane-spanning sequences of the gp52 glycoprotein are required for the pathogenicity of Friend spleen focus-forming virus.

Authors:  R V Srinivas; D R Kilpatrick; S Tucker; Z Rui; R W Compans
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

6.  An array of novel murine spleen focus-forming viruses that activate the erythropoietin receptor.

Authors:  E Gomez-Lucia; Y Zhi; M Nabavi; W Zhang; D Kabat; M E Hoatlin
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 7.  Erythropoietin receptor. Subunit structure and activation.

Authors:  A D D'Andrea; L I Zon
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

8.  Both the polycythemia- and anemia-inducing strains of Friend spleen focus-forming virus induce constitutive activation of the Raf-1/mitogen-activated protein kinase signal transduction pathway.

Authors:  K W Muszynski; T Ohashi; C Hanson; S K Ruscetti
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

9.  Glycosylation of glycoprotein 55 encoded by the anaemia-inducing strain of Friend spleen focus-forming virus.

Authors:  J Völker; H Geyer; R Geyer
Journal:  Glycoconj J       Date:  1994-04       Impact factor: 2.916

10.  Activation of the N-terminally truncated form of the Stk receptor tyrosine kinase Sf-Stk by Friend virus-encoded gp55 is mediated by cysteine residues in the ecotropic domain of gp55 and the extracellular domain of Sf-Stk.

Authors:  Shihan He; Shuang Ni; Shailaja Hegde; Xin Wang; Daniel R Sharda; Avery August; Robert F Paulson; Pamela A Hankey
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.